

Welche Veranstaltung planen Sie gerade ?

Wir unterstützen Sie bei

- Regional- und Fachtagungen
- Kongressen
- Symposien
- Workshops
- Seminaren



vokativ
alte & neue medien

Public Relations

Veranstaltungsorganisation

Verbands-
& Vereinsmanagement

Mediengestaltung

eService

Dear Colleagues

Following our quite successful 2011 Munich conference on "Radiation Oncology in Prostate Cancer", we are proud once again to host a radiation oncology meeting distinguished by renowned speakers and chairs. The scientific program has been organized in close cooperation with the radiation oncology departments of the "Technische Universität München" and the "Krankenhaus Barmherzige Schwestern Linz". This year, we have included bladder cancer as a second disease entity, which -similar to prostate cancer- is a urologic tumor that can be cured by radio(chemo)therapy. In addition, new topics such as stereotactic prostate radiation therapy, focal treatment and laser based protons are integral parts of this conference. New developments with regard to imaging, hypofractionation, brachytherapy and treatment of recurrence are being eagerly awaited and will be discussed. The meeting will be concluded with our ritual "battle" between dedicated followers of proton versus photon treatment.

2013 is a special year for the Department of Radiation Oncology of the TU München as both Prof. Molls and Prof. Geinitz are leaving the clinic. Thus, the pre-conference on March 7th entitled "37 years of radiation research – a Darwinian evolution?" is dedicated to highlighting the development of radiobiology, medical physics and radiooncology during the last three decades. Fellow research colleagues and clinical partners of Prof. Molls will be leading us through the program.

We are confident that the conference will again provoke vivid discussions and may even contribute to the further evolution of radio-uro-oncology. We look forward to seeing you in pre-spring in the Bavarian capital where the "Biergarten" and palace parks will be beginning to flourish.



Prof. Dr.
Michael Molls
Chair Munich



Prof. Dr.
Hans Geinitz
Chair Linz



PD Dr.
Barbara Röper
Vice chair
Munich



Dr.
Nona Duma
Senior physician
Munich

Congress Venue:

Klinikum rechts der Isar, Technische Universität München
Hörsäle (Lecture halls)
Ismaninger Straße 22, 81675 Munich, Germany

Organization:

Department of Radiation Oncology
Technische Universität München
Barbara Hofbauer, Dipl.-BW

For registration and further information please visit:
www.prostate-radiation-oncology.de

Contact:

vokativ GmbH, roc@vokativ.de
T: 0049-551-48857-409

Early bird registration (until January 18th, 2013): 170 Euros
Late and onsite registration: 230 Euros

Students:

Early bird registration (until January 18th, 2013): 50 Euros
Late and onsite registration: 70 Euros

The conference fee includes participation in the pre-conference on Thursday (March 7th, 2013). The Social Dinner on March 8th will be charged with 30 Euros.

CME points: Pre-conference 7 points
Main conference 13 points
(Bayerische Landesärztekammer)



Klinikum rechts der Isar
Technische Universität München



Roman-Herzog-Krebszentrum
Comprehensive Cancer Center




Radiation Oncology in Prostate and Bladder Cancer – Current and Future Concepts

Prof. Michael Molls:
37 Years of Radiation Research
and 21 Years at the TU München

Pre-Conference: March 7, 2013
Conference: March 8 - 9, 2013

Klinikum rechts der Isar
Technische Universität München (TU Munich)



Radiation Oncology in Prostate and Bladder Cancer – Current and Future Concepts

Foto Patrick Hübgen

Pre-Conference - 37 Years of Radiation Research A Darwinian Evolution ?

Thursday, March 7, 2013 Hörsaal (Lecture hall): Pavillon	
12:00 – 12:15	Welcome address <i>Hans Geinitz, Chair Department of Radiation Oncology Linz Peter Henningsen Dean Medical Faculty, TUM</i>
	Keynote lecture <i>Chair: J. Wilkens</i>
12:15 - 12:40	Interdisciplinary research at the interface of physics and biomedicine: the benefit for modern societies and the MAP Cluster of Excellence. <i>F. Krausz, Munich</i>
	Radiobiological evolution <i>Chairs: C. Streffer, B. Röper</i>
12:40 - 13:00	From pre-implantation mouse embryos over cancer stem cells to combined radiation-immune therapy. <i>G. Multhoff, Munich</i>
13:00 - 13:20	Hypoxia – still a threat for radiation oncology and radiation oncologists? <i>P. Vaupel, Munich</i>
13:20 - 13:35	Radiation biology of laser induced protons and heavy ions. <i>T. Schmid, Munich</i>
13:35 – 13:55	Normal tissue radiation injury: how will radio-biology help to save organs at risk? <i>M. Atkinson, Munich</i>
13:55 – 14:15	Discussion
14:15 – 14:35	Coffee break
	Medical physics evolution <i>Chairs: P. Kneschaurek, N. Zamboglou</i>
14:35 – 14:55	Radiotherapy facilities – do we need all the fancy novelties? <i>F. Nüsslin, Munich</i>
14:55 – 15:15	Stereotactic body radiotherapy – successful implementation as a consequence of close cooperation of radiation oncology and medical physics. <i>F. Zimmermann, Basel</i>
15:15 – 15:35	IMRT and protons: is physics the driver for a better treatment? <i>T. Bortfeld, Boston</i>
15:35 – 15:55	Discussion
15:55 - 16:15	Coffee break

	Radio-oncology evolution <i>Chairs: H.J. Feldmann, J. Debus</i>
16:15 – 16:35	Essentials of tumor radiation biology. <i>K. R. Trott, Munich</i>
16:35 – 16:55	Where are the innovations in clinical and translational research in radiation oncology? <i>A. Grosu, Freiburg</i>
16:55 – 17:15	Treatment concepts – innovation triggered by patients? <i>C. Nieder, Bodø</i>
17:15 – 17:35	Scientific ethics and clinical studies. <i>P. Lukas, Innsbruck</i>
17:35 – 17:55	Discussion
17:55 – 18:15	Michael Molls: 37 years of radiation research. <i>T. Herrmann, Dresden</i>
18:15	End of pre-conference

Conference - Radiation Oncology in Prostate and Bladder Cancer

Friday, March 8, 2013 Hörsaal (Lecture hall): A	
08:30 - 08:40	Welcome address <i>Hans Geinitz, Chair Department of Radiation Oncology Linz Reiner Gradinger - Medical Director TUM Michael Molls, Chair Department of Radiation Oncology TUM</i>
	Imaging and delineation <i>Chairs: A. Grosu, E. Rummeny</i>
08:40 - 09:00	New X-ray imaging modalities: will brilliant CT come into the clinic in the upcoming years? <i>F. Pfeiffer, Munich</i>
09:00 - 09:20	New PET tracers and biomarkers for the staging of prostate cancer. <i>W. Lilleby, Oslo</i>
09:20 - 09:40	MRI imaging: sensitivity and specificity for intraprostatic lesion boost. <i>M. Reiser, Munich</i>
09:40 - 10:00	Safety margins with IMRT and IGRT: how much is large enough? <i>F. Wenz, Mannheim</i>
10:00 - 10:20	Discussion
10:20 - 10:40	Coffee Break
	Radiation therapy techniques <i>Chairs: S. Fosså, D. Vordermark</i>
10:40 - 11:00	IMRT for prostate cancer – total doses and dose constraints. <i>S. Fosså, Oslo</i>
11:00 - 11:20	IGRT for prostate cancer – implanted markers vs. on board CT. <i>N. Duma, Munich</i>

11:20 – 11:40	Radiation therapy for bladder cancer: target volumes and doses. <i>J. Dunst, Lübeck</i>
11:40 - 12:00	Discussion
12:00 - 12:20	Coffee Break
	... with regard to overall survival <i>Chairs: P. Warde, JH Kaanders</i>
12:20 - 12:40	Does radiation therapy increase the survival in patients with prostate cancer? <i>P. Warde, Toronto</i>
12:40 – 13:00	Does surgery increase the survival in patients with prostate cancer? <i>J. Gschwend, Munich</i>
13:00 - 13:20	More late toxicity and decreased quality of life – the trade-offs for a better survival? <i>R. Pötter, Wien</i>
13:20 – 13:40	Discussion
13:40 – 15:10	Lunch and industrial exhibition
	Conservative treatment vs. radical surgery <i>Chairs: J. Gschwend, C. Belka</i>
15:10 – 15:30	Comparative trials on radiation therapy vs. surgery for prostate cancer. <i>D. Böhmer, Berlin</i>
15:30 - 15:50	Comparative trials on radiation therapy vs. surgery for bladder cancer. <i>C. Rödel, Frankfurt</i>
15:50 – 16:10	Discussion
	Controversy: whole organ treatment vs. lesion boost <i>Chairs: M. Kollmeier, M. Stuschke</i>
16:10 – 16:30	Focal radiation therapy in prostate cancer: when, how and why? <i>M. Kamrava, Los Angeles</i>
16:30 – 16:50	Focal radiation therapy in bladder cancer: time for dose escalation? <i>M. Kollmeier, New York</i>
16:50 - 17:10	Discussion
17:10 – 17:30	Coffee break
	Hypofractionation and stereotactic treatment <i>Chairs: D. Dearnaley, N. Duma</i>
17:30 - 17:50	New trials on hypofractionation for prostate cancer. <i>D. Dearnaley, London</i>
17:50 - 18:10	Stereotactic treatment for prostate cancer: how and why? <i>M. Guckenberger, Würzburg</i>
18:10 – 18:30	Hypofractionation or acceleration for bladder cancer? <i>S. Combs, Heidelberg</i>
18:30 - 18:50	Discussion
20:00	Conference dinner

Saturday, March 9, 2013 Hörsaal (Lecture hall): A	
	Brachytherapy <i>Chairs: K. Kapp, O. Kölbl</i>
9:00 - 9:20	HDR brachytherapy: new techniques and recent trials. <i>N. Zamboglou, Offenbach</i>
9:20 - 9:40	Seed implantation: moving towards treatment of intermediate risk patients? <i>M. Flentje, Würzburg</i>
9:40 - 10:00	Discussion
10:00 - 10:20	Coffee Break
	Treatment of recurrence <i>Chairs: H. Geinitz, F. Sedlmayer</i>
10:20 - 10:40	Biochemical recurrence after definitive radiotherapy – how long can we watch and wait? <i>F. Lohr, Mannheim</i>
10:40 - 11:00	Systemic therapy for biochemical recurrence: how and when? <i>H. Kübler, Munich</i>
11:00 - 11:20	Recurrence after radiation therapy: local therapy- how and when? <i>W. Loidl, Linz</i>
11:20 - 11:40	Recurrence after radical prostatectomy: new trials on salvage-treatment. <i>G. Goldner, Wien</i>
11:40 - 12:10	Discussion
12:10 - 13:30	Lunch and industrial exhibition
	Controversy: protons and heavy ions vs. photons <i>Chairs: M. Molls, V. Budach</i>
13:30 - 13:50	Treating patients on trials in proton facilities: where do we stand? <i>R. Schneider, Villigen</i>
13:50 - 14:10	New evidence for the superiority of protons or heavy ions in prostate cancer treatment. <i>J. Debus, Heidelberg</i>
14:10 - 14:30	New evidence against the superiority of protons or heavy ions in prostate cancer treatment. <i>N. van As, Sutton</i>
14:30 - 14:50	Discussion
14:50	Closing Remarks